Literature DB >> 11450957

Enhancement of hyperglycemia-induced acidification of human melanoma xenografts with inhibitors of respiration and ion transport.

R Zhou1, N Bansal, D B Leeper, S Pickup, J D Glickson.   

Abstract

RATIONALE AND
OBJECTIVES: The authors performed this study to evaluate the selective acidification of a human melanoma xenograft in mice with severe combined immunodeficiency with the induction of hyperglycemia (mean blood glucose level +/- standard error of the mean, 26 mmol/L +/- 1) and the intraperitoneal administration of metaiodobenzylguanidine (MIBG, 30 mg/kg), alpha-cyano-4-hydroxycinnamate (CNCn, 300 mg/kg), lonidamine (100 mg/kg), cariporide (HOE642, 160 mg/kg), or 4.4'-diisothiocyanatostilbene-2, 2'-disulfonic acid (DIDS, 50 mg/kg).
MATERIALS AND METHODS: The intra- and extracellular pH levels of tumor were estimated from the chemical shifts of inorganic phosphate and 3-aminopropylphosphonate, respectively, with phosphorus-31 nuclear magnetic resonance (MR) spectroscopy. The relative level of steady-state lactate was monitored with hydrogen-1 MR spectroscopy.
RESULTS: In small tumors (< or = 8.0 mm), hyperglycemia decreased the intra- and extracellular pH levels by less than 0.2. The combination of hyperglycemia and MIBG decreased the intra- and extracellular pH levels by approximately 0.4 and 0.6, respectively, and lowered the beta-nucleoside triphosphate (NTP)/inorganic phosphate (Pi) ratio of tumor and liver by about 60% and 25%, respectively. The combination of hyperglycemia, MIBG, and CNCn produced a transient decrease in the intracellular pH of about 0.6. The combination of hyperglycemia and lonidamine produced a sustained (>3 hours) 0.8-unit decrease in intracellular pH and an 83% and 100% decrease in PCr/P1 and beta-NTP/P1 ratios, respectively. The combination of hyperglycemia. MIBG, cariporide, and DIDS produced a gradual decrease in intra- and extracellular pH by 1.1 and 1.0, respectively. The relative level of steady-state lactate concentration in tumors increased 10% with hyperglycemia alone, about 20% with MIBG plus hyperglycemia, and increased more than twofold when hyperglycemia was combined with MIBG and CNCn administration.
CONCLUSION: These preliminary data suggest that hyperglycemia and combinations of respiratory and ion transport inhibitors can be used to selectively acidify tumors and, thereby, sensitize them to hyperthermnia or other pH-sensitive therapeutic modalities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11450957     DOI: 10.1016/S1076-6332(03)80681-5

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  9 in total

1.  Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan.

Authors:  Kavindra Nath; David S Nelson; Daniel F Heitjan; Rong Zhou; Dennis B Leeper; Jerry D Glickson
Journal:  NMR Biomed       Date:  2015-03       Impact factor: 4.044

2.  Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.

Authors:  Kavindra Nath; David S Nelson; Daniel F Heitjan; Dennis B Leeper; Rong Zhou; Jerry D Glickson
Journal:  NMR Biomed       Date:  2014-12-12       Impact factor: 4.044

Review 3.  Manipulating extracellular tumour pH: an effective target for cancer therapy.

Authors:  Guanyu Hao; Zhi Ping Xu; Li Li
Journal:  RSC Adv       Date:  2018-06-19       Impact factor: 4.036

4.  Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets.

Authors:  Vera Miranda-Gonçalves; Mrinalini Honavar; Céline Pinheiro; Olga Martinho; Manuel M Pires; Célia Pinheiro; Michelle Cordeiro; Gil Bebiano; Paulo Costa; Isabel Palmeirim; Rui M Reis; Fátima Baltazar
Journal:  Neuro Oncol       Date:  2012-12-20       Impact factor: 12.300

Review 5.  Mechanism of antineoplastic activity of lonidamine.

Authors:  Kavindra Nath; Lili Guo; Bethany Nancolas; David S Nelson; Alexander A Shestov; Seung-Cheol Lee; Jeffrey Roman; Rong Zhou; Dennis B Leeper; Andrew P Halestrap; Ian A Blair; Jerry D Glickson
Journal:  Biochim Biophys Acta       Date:  2016-08-04

6.  (31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan.

Authors:  Kavindra Nath; David S Nelson; Andrew M Ho; Seung-Cheol Lee; Moses M Darpolor; Stephen Pickup; Rong Zhou; Daniel F Heitjan; Dennis B Leeper; Jerry D Glickson
Journal:  NMR Biomed       Date:  2012-06-29       Impact factor: 4.044

7.  The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters.

Authors:  Bethany Nancolas; Lili Guo; Rong Zhou; Kavindra Nath; David S Nelson; Dennis B Leeper; Ian A Blair; Jerry D Glickson; Andrew P Halestrap
Journal:  Biochem J       Date:  2016-02-01       Impact factor: 3.857

8.  Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice.

Authors:  Kavindra Nath; David S Nelson; Mary E Putt; Dennis B Leeper; Bradley Garman; Katherine L Nathanson; Jerry D Glickson
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

Review 9.  Brain Tumor Diagnostics and Therapeutics with Superparamagnetic Ferrite Nanoparticles.

Authors:  Fahmeed Hyder; S Manjura Hoque
Journal:  Contrast Media Mol Imaging       Date:  2017-12-11       Impact factor: 3.161

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.